Skip to main content
main-content

Nephropathy

News

05-05-2020 | Prediabetes | Highlight | News

Prediabetes marks increased vascular risk

People who meet the criteria for prediabetes during the 3 years before a type 2 diabetes diagnosis have a higher burden of vascular disease than those who do not, research shows.

04-29-2020 | Nephropathy | News

Real-world data back renal benefits with SGLT2 inhibition

Use of sodium-glucose cotransporter 2 inhibitors is associated with a reduced risk for renal events in people with type 2 diabetes in clinical practice, say researchers.

04-23-2020 | GLP-1 agonists | News

Real-world evidence for renoprotective effects of GLP-1 receptor agonists

People with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists have a lower risk for serious renal adverse events than those given dipeptidyl peptidase-4 inhibitors, indicate results from a Scandinavian real-world study.

Read more

Related topics

Superior

Related

Opinion

08-06-2019 | SGLT2 inhibitors | Editorial | Article

Cardiorenal syndromes and SGLT2 inhibitor usage

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity.

05-08-2017 | Metformin | Editorial | Article

Metformin: What is new with this old medication?

With the arrival of slow-release formulations of metformin and the relaxation of guidelines concerning its use in patients with kidney disease, Carol Wysham explains how the population of patients who might benefit from this medication has expanded.

11-04-2016 | Clinical trial | Editorial | Article

My EASD 2016 Highlights: From Paleolithic diets to the artificial pancreas

Editorial board member John Wilding outlines key moments from the 52nd annual meeting of the European Association for the Study of Diabetes in Munich, Germany.

Journal articles and book chapters

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

09-08-2018 | Nephropathy | Review | Article

Metabolic abnormalities in diabetes and kidney disease: Role of uremic toxins

Koppe L, Fouque D, Soulage CO. Curr Diab Rep 2018; 18: 97. doi: 10.1007/s11892-018-1064-7

08-15-2018 | Nephropathy | Review | Article

Inpatient glycemic management in the setting of renal insufficiency/failure/dialysis

Iyengar R, Franzese J, Gianchandani R. Curr Diab Rep 2018; 18: 75. doi: 10.1007/s11892-018-1044-y

Case reports

Image Credits